Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, TRI

HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout


CHARLOTTESVILLE, Va., July 9, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) to discover and develop novel therapeutics for gout. In fewer than 18 months, HemoShear's team has made significant progress and the company will receive an undisclosed milestone payment in accordance with the agreement with Horizon, which was executed in January 2019.

"The collaboration with the Horizon team has been very productive; together we are a great team combining Horizon's expertise in gout with HemoShear's discovery platform for novel therapeutics," said Brian Wamhoff, PhD, chief operating officer and head of innovation, HemoShear. "Our scientists have generated valuable insights into the gout disease process and potential treatment approaches in an accelerated timeframe."

Under the terms of the January 2019 agreement, HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear's proprietary disease modeling platform to discover new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon will make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed.  

Gout is a chronic, progressive inflammatory form of arthritis that is caused by excess uric acid in the body, and needs to be managed aggressively.  If uric acid levels in the blood remain elevated, thin rod-like crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling and joint damage. In addition to the joint damage, urate crystals can also deposit in other organs of the body, and if left unmanaged, gout can lead to significant tissue damage.  Uncontrolled gout occurs when people living with gout continue to have high levels of uric acid and gout symptoms despite the use of standard oral urate-lowering therapies.

In addition to advancing its program with Horizon, HemoShear recently announced authorization from the FDA to proceed with a Phase 2 study of its proprietary oral small molecule drug for methylmalonic acidemia and propionic acidemia. 

About HemoShear Therapeutics

HemoShear Therapeutics is a privately held clinical stage company developing treatments for rare metabolic disorders with significant unmet patient need. HemoShear's drug discovery platform, REVEAL-Txtm, enables the Company's scientists to create best-in-class, biologically relevant human disease models to uncover the underlying mechanisms of disease, translate those discoveries into drug targets, and select candidates that may treat patients successfully. In addition to the Company's proprietary rare disease programs, HemoShear has exclusive partnerships to identify novel therapeutic approaches in nonalcoholic steatohepatitis (NASH) with Takeda and in gout with Horizon Therapeutics.   For more information visit www.HemoShear.com.

SOURCE HemoShear Therapeutics


These press releases may also interest you

at 10:15
The Micro-electro-mechanical System (MEMS) market is projected to grow from USD 16.5 billion in 2024 and is estimated to reach USD 24.2 billion by 2029; it is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.9% from 2024 to 2029...

at 10:12
NerdsToGo®, a leading information technology (IT) solutions and technology repair services franchise for both business and home, announced today plans for its strategic expansion throughout the greater Chicago area with 20 new territories available...

at 10:11
TeachTown, a leading provider of special education curriculum for students with moderate to severe disabilities, is pleased to announce that its K-12 standards-based, adapted core curriculum, enCORE, has been named a finalist in 2 categories of the...

at 10:05
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution deals....

at 10:01
The Predictive Maintenance Market is estimated to grow from USD 10.6...

at 10:00
Frost & Sullivan recently researched the customer experience outsourcing services industry and, based on its findings, recognizes AeC with the 2023 Company of the Year Award. AeC is connecting technology with outstanding customer service to increase...



News published on and distributed by: